Admiring eyes on a cancer portfolio that makes Merck KGaA an 'oncology leader,' says Zhen Su

3 August 2018

“The innovation and transformative potential that this pipeline holds really give us a lot of confidence that we are going to emerge as a strong player in the oncology space.”

Those are the words of Zhen Su, head of Merck KGaA’s (MRK: DE) global oncology medical affairs division, when asked to reflect on a pipeline that the German company has progressed this year with data presentations at the American Society for Medical Oncology (ASCO), in particular.

Indeed, in one of the most common cancer types, Dr Su says that this year’s meeting was “one of the most exciting ASCO meetings we've had,” with compelling Phase I and II data presentations.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK